| Acute Leukemia |
1 |
1 |
| Leukemia |
0 |
0.97 |
| Toxicology |
0 |
0.62 |
| Cancer |
0 |
0.53 |
| Child |
0 |
0.98 |
| Biologic Therapy |
0 |
0.47 |
| Acute Myeloblastic Leukemia |
0 |
0.46 |
| Targeted Cancer Therapy |
0 |
0.41 |
| Cancer Survivor |
0 |
0.4 |
| Genomic Medicine |
0 |
0.35 |
| Cancer in Childhood |
0 |
0.99 |
| Adolescent Medicine |
0 |
0.96 |
| Young Adult |
0 |
0.28 |
| Blood |
0 |
0.06 |
| Canada |
0 |
0.06 |
| Face |
0 |
0.06 |
| Lymphoma |
0 |
0.06 |
| Plague |
0 |
0.06 |
| Tropical Diseases |
0 |
0.06 |
| Stem Cell Research and Therapy |
0 |
0.05 |
| Adverse Effects |
0 |
0.03 |
| CAR-T |
0 |
0.03 |
| Centers for Disease Control and Prevention |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Epidemiology |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Fellowship |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Healthcare and Medical Technology |
0 |
0.03 |
| Neuroendocrine Tumor |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |
| Pedal |
0 |
0.03 |
| Preventive Screening |
0 |
0.03 |
| Remission |
0 |
0.03 |
| Texas |
0 |
0.03 |
| Transplantation |
0 |
0.03 |
| UK Site Content |
0 |
0.03 |